The invention relates to a combination medicament comprising a human interleukin-2 (hIL-2)-specific monoclonal antibody (mAb), or antigen binding fragment thereof, the binding of which to hIL-2 inhibits binding of hIL-2 to CD25, and an immune checkpoint inhibitor agent. The hIL-2 antibody can be given without or with recombinant hIL-2 and is characterized by any of the parameters: the variable chain of the mAb comprises the amino acid sequence of SEQ ID NO 005 or SEQ ID NO 006 the binding to hIL-2 is characterized by a dissociation constant (KD) = 7,5 nmol/L the binding to hIL-2 is characterized by an off-rate (Koff) = 1x10-4 s-1 and/or the antibody displays no measurable cross-reactivity to murine IL-2.
